Journal of Traditional and Complementary Medicine (Mar 2024)

Curcumin in treatment of hematological cancers: Promises and challenges

  • Maliheh Entezari,
  • Armita Tayari,
  • Mahshid Deldar Abad Paskeh,
  • Simin Khorsand Kheirabad,
  • Sahar Naeemi,
  • Afshin Taheriazam,
  • Hossein Dehghani,
  • Shokooh Salimimoghadam,
  • Mehrdad Hashemi,
  • Sepideh Mirzaei,
  • Saeed Samarghandian

Journal volume & issue
Vol. 14, no. 2
pp. 121 – 134

Abstract

Read online

Hematological cancers include leukemia, myeloma and lymphoma and up to 178.000 new cases are diagnosed with these tumors each year. Different kinds of treatment including radiotherapy, chemotherapy, immunotherapy and stem cell transplantation have been employed in the therapy of hematological cancers. However, they are still causing death among patients. On the other hand, curcumin as an anti-cancer agent for the suppression of human cancers has been introduced. The treatment of hematological cancers using curcumin has been followed. Curcumin diminishes viability and survival rate of leukemia, myeloma and lymphoma cells. Curcumin stimulates apoptosis and G2/M arrest to impair progression of tumor. Curcumin decreases levels of matrix metalloproteinases in suppressing cancer metastasis. A number of downstream targets including VEGF, Akt and STAT3 undergo suppression by curcumin in suppressing progression of hematological cancers. Curcumin stimulates DNA damage and reduces resistance of cancer cells to irradiation. Furthermore, curcumin causes drug sensitivity of hematological tumors, especially myeloma. For targeted delivery of curcumin and improving its pharmacokinetic and anti-cancer features, nanostructures containing curcumin and other anti-cancer agents have been developed.

Keywords